Insider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) Director Sells $94,054.00 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) Director Joshua Phillips sold 12,710 shares of the firm’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $7.40, for a total transaction of $94,054.00. Following the completion of the transaction, the director now owns 5 shares in the company, valued at $37. The trade was a 99.96 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Joshua Phillips also recently made the following trade(s):

• On Monday, January 13th, Joshua Phillips sold 12,163 shares of Sera Prognostics stock. The stock was sold at an average price of $6.39, for a total transaction of $77,721.57.

Sera Prognostics Stock Performance

Shares of NASDAQ:SERA opened at $6.42 on Friday. The stock’s 50-day moving average is $7.37 and its 200-day moving average is $7.31. The company has a market cap of $216.80 million, a P/E ratio of -6.48 and a beta of 0.86. Sera Prognostics, Inc. has a 52-week low of $4.98 and a 52-week high of $12.35.

Sera Prognostics (NASDAQ:SERA) last released its earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.09 million. During the same quarter in the prior year, the business earned ($0.23) earnings per share. As a group, equities analysts predict that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Hedge Funds Weigh In On Sera Prognostics

A number of institutional investors and hedge funds have recently bought and sold shares of SERA. Bank of New York Mellon Corp boosted its holdings in Sera Prognostics by 100.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock valued at $892,000 after purchasing an additional 75,441 shares during the period. Rhumbline Advisers acquired a new position in shares of Sera Prognostics during the second quarter valued at about $190,000. American Century Companies Inc. lifted its stake in shares of Sera Prognostics by 12.7% in the second quarter. American Century Companies Inc. now owns 25,682 shares of the company’s stock valued at $152,000 after buying an additional 2,891 shares during the period. Renaissance Technologies LLC acquired a new stake in Sera Prognostics during the second quarter worth about $162,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Sera Prognostics during the second quarter worth about $68,000. Institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.